DD279407A1 - Verfahren zur herstellung eines mittels gegen aids - Google Patents

Verfahren zur herstellung eines mittels gegen aids Download PDF

Info

Publication number: DD279407A1
Authority: DD; German Democratic Republic
Prior art keywords: substituted; preparation; aids; agent against; agent
Prior art date: 1986-07-24

Application number

DD86292826A

Other languages

German (de)

English (en)

Inventor

Eckart Matthes

Christine Lehmann

Dieter Scholz

Martin Von Janta-Lipinski

Klaus Gaertner

Peter Langen

Hans-Alfred Rosenthal

Original Assignee

Akad Wissenschaften Ddr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-07-24

Filing date

1986-07-24

Publication date

1990-06-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27426554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD279407(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1986-07-24 Priority to DD86292826A priority Critical patent/DD279407A1/de

1986-07-24 Application filed by Akad Wissenschaften Ddr filed Critical Akad Wissenschaften Ddr

1987-06-03 Priority to DD87303489A priority patent/DD281346A5/de

1987-07-21 Priority to DK378687A priority patent/DK378687A/da

1987-07-21 Priority to DE8787110542T priority patent/DE3765045D1/de

1987-07-21 Priority to EP87110542A priority patent/EP0254268B2/de

1987-07-21 Priority to ES87110542T priority patent/ES2036196T5/es

1987-07-23 Priority to JP62182423A priority patent/JP2525418B2/ja

1988-03-03 Priority to AU12592/88A priority patent/AU615431B2/en

1988-03-10 Priority to NZ223836A priority patent/NZ223836A/en

1988-07-07 Priority to CA000571404A priority patent/CA1333390C/en

1988-07-15 Priority to US07/223,677 priority patent/US4963662A/en

1990-06-06 Publication of DD279407A1 publication Critical patent/DD279407A1/de

1990-08-13 Priority to US07/566,486 priority patent/US5153180A/en

1990-12-19 Priority to GR90401088T priority patent/GR3001214T3/el

1994-05-31 Priority to CA000616868A priority patent/CA1336820C/en

Links

208000030507 AIDS Diseases 0.000 title claims abstract 3
238000004519 manufacturing process Methods 0.000 title description 3
239000003795 chemical substances by application Substances 0.000 claims abstract description 7
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims abstract description 6
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims abstract description 6
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims abstract description 6
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims abstract description 6
208000029483 Acquired immunodeficiency Diseases 0.000 claims abstract description 3
229930024421 Adenine Natural products 0.000 claims abstract description 3
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims abstract description 3
229960000643 adenine Drugs 0.000 claims abstract description 3
229940104302 cytosine Drugs 0.000 claims abstract description 3
150000003230 pyrimidines Chemical class 0.000 claims abstract description 3
229940113082 thymine Drugs 0.000 claims abstract description 3
229940035893 uracil Drugs 0.000 claims abstract description 3
238000001802 infusion Methods 0.000 claims description 3
239000002504 physiological saline solution Substances 0.000 claims description 3
231100000676 disease causative agent Toxicity 0.000 claims description 2
238000010253 intravenous injection Methods 0.000 claims description 2
238000000034 method Methods 0.000 claims 4
150000001875 compounds Chemical class 0.000 claims 3
239000000203 mixture Substances 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 2
239000003978 infusion fluid Substances 0.000 abstract description 2
238000002347 injection Methods 0.000 abstract description 2
239000007924 injection Substances 0.000 abstract description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 abstract 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
102100034343 Integrase Human genes 0.000 description 4
239000000126 substance Substances 0.000 description 4
241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 3
241000700605 Viruses Species 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
239000008298 dragée Substances 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229960005314 suramin Drugs 0.000 description 2
235000011178 triphosphate Nutrition 0.000 description 2
239000001226 triphosphate Substances 0.000 description 2
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
229940124718 AIDS vaccine Drugs 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229930194076 Germanin Natural products 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
208000018555 lymphatic system disease Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

DD86292826A 1986-07-24 1986-07-24 Verfahren zur herstellung eines mittels gegen aids DD279407A1 (de)

Priority Applications (14)

Application Number	Priority Date	Filing Date	Title
DD86292826A DD279407A1 (de)	1986-07-24	1986-07-24	Verfahren zur herstellung eines mittels gegen aids
DD87303489A DD281346A5 (de)	1986-07-24	1987-06-03	Verfahren zur herstellung eines mittels gegen hiv-infektionen beim menschen
DK378687A DK378687A (da)	1986-07-24	1987-07-21	Laegemiddel, fremgangsmaade til dets fremstilling og anvendelse mod hiv-infektioner hos mennesker
DE8787110542T DE3765045D1 (de)	1986-07-24	1987-07-21	Fluorierte nucleoside, ihre herstellung und ihre pharmazeutische verwendung gegen aids.
EP87110542A EP0254268B2 (de)	1986-07-24	1987-07-21	Fluorierte Nucleoside, ihre Herstellung und ihre pharmazeutische Verwendung gegen AIDS
ES87110542T ES2036196T5 (es)	1986-07-24	1987-07-21	Nucleosidos fluorados, su preparacion y su empleo farmaceutico contra el sida.
JP62182423A JP2525418B2 (ja)	1986-07-24	1987-07-23	後天性免疫不全症ａｉｄｓに対する医薬
AU12592/88A AU615431B2 (en)	1986-07-24	1988-03-03	Fluorinated nucleosides: method for their preparation and use as drugs against the human acquired immunodeficiency syndrome (aids)
NZ223836A NZ223836A (en)	1986-07-24	1988-03-10	Fluorinated nucleosides: anti-aids drugs
CA000571404A CA1333390C (en)	1986-07-24	1988-07-07	Fluorinated nucleosides and process for treating retrovirus infections therewith
US07/223,677 US4963662A (en)	1986-07-24	1988-07-15	Fluorinated nucleosides and method for treating retrovirus infections therewith
US07/566,486 US5153180A (en)	1986-07-24	1990-08-13	Fluorinated nucleosides and process for treating retrovirus infections therewith
GR90401088T GR3001214T3 (en)	1986-07-24	1990-12-19	Fluorinated nucleosides,their preparation and their pharmaceutical use against aids
CA000616868A CA1336820C (en)	1986-07-24	1994-05-31	Fluorinated nucleosides and process for treating retrovirus infections therewith

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DD86292826A DD279407A1 (de)	1986-07-24	1986-07-24	Verfahren zur herstellung eines mittels gegen aids
DD30257387		1987-05-08
DD87303489A DD281346A5 (de)	1986-07-24	1987-06-03	Verfahren zur herstellung eines mittels gegen hiv-infektionen beim menschen
CA000571404A CA1333390C (en)	1986-07-24	1988-07-07	Fluorinated nucleosides and process for treating retrovirus infections therewith

Publications (1)

Publication Number	Publication Date
DD279407A1 true DD279407A1 (de)	1990-06-06

Family

ID=27426554

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DD86292826A DD279407A1 (de)	1986-07-24	1986-07-24	Verfahren zur herstellung eines mittels gegen aids
DD87303489A DD281346A5 (de)	1986-07-24	1987-06-03	Verfahren zur herstellung eines mittels gegen hiv-infektionen beim menschen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DD87303489A DD281346A5 (de)	1986-07-24	1987-06-03	Verfahren zur herstellung eines mittels gegen hiv-infektionen beim menschen

Country Status (11)

Country	Link
US (1)	US4963662A (da)
EP (1)	EP0254268B2 (da)
JP (1)	JP2525418B2 (da)
AU (1)	AU615431B2 (da)
CA (2)	CA1333390C (da)
DD (2)	DD279407A1 (da)
DE (1)	DE3765045D1 (da)
DK (1)	DK378687A (da)
ES (1)	ES2036196T5 (da)
GR (1)	GR3001214T3 (da)
NZ (1)	NZ223836A (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458772B1 (en)	1909-10-07	2002-10-01	Medivir Ab	Prodrugs
US6448392B1 (en)	1985-03-06	2002-09-10	Chimerix, Inc.	Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5223263A (en) *	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
US5446029A (en) *	1986-07-04	1995-08-29	Medivir Ab	Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides
US5153180A (en) *	1986-07-24	1992-10-06	Eckart Matthes	Fluorinated nucleosides and process for treating retrovirus infections therewith
WO1988003804A2 (en) *	1986-11-21	1988-06-02	Max-Planck-Gesellschaft Zur Förderung Der Wissensc	Method of treating viral infections in humans and compositions therefor
US5459256A (en) *	1987-04-17	1995-10-17	The Government Of The United States Of America As Represented By The Department Of Health And Human Services	Lipophilic, aminohydrolase-activated prodrugs
US5495010A (en) *	1987-04-17	1996-02-27	The United States Of America As Represented By The Department Of Health And Human Services	Acid stable purine dideoxynucleosides
GB8719877D0 (en) *	1987-08-22	1987-09-30	Wellcome Found	Antiviral compounds
JPS6468395A (en) *	1987-09-08	1989-03-14	Yamasa Shoyu Kk	3'-deoxyarbinofuranosylpyrimidine nucleoside derivative
JPH01265099A (ja) *	1987-10-08	1989-10-23	Stichting Rega Vzw	抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5506215A (en) *	1987-11-03	1996-04-09	Medivir Ab	1-(3'-fluoro-2',3'-dideoxy-β-D-ribofuranosyl)-5-substituted pyrimidine nucleosides
SE8704298D0 (sv) *	1987-11-03	1987-11-03	Astra Ab	Compounds for use in therapy
GB8726136D0 (en) *	1987-11-07	1987-12-09	Wellcome Found	Therapeutic nucleosides
EP0316592A3 (en) *	1987-11-13	1990-09-19	Stichting REGA V.Z.W.	3'-fluoro-2',3'-dideoxyuridine, and its therapeutic application
US4997926A (en) *	1987-11-18	1991-03-05	Scripps Clinic And Research Foundation	Deaminase-stable anti-retroviral 2-halo-2',3'-dideoxy
US5817638A (en) *	1988-07-07	1998-10-06	Nexstar Pharmaceuticals, Inc.	Antiviral liponucleosides: treatment of hepatitis B
US6252060B1 (en)	1988-07-07	2001-06-26	Nexstar Pharmaceuticals, Inc.	Antiviral liponucleosides: treatment of hepatitis B
US6599887B2 (en)	1988-07-07	2003-07-29	Chimerix, Inc.	Methods of treating viral infections using antiviral liponucleotides
EP0355031A3 (de) *	1988-08-17	1990-12-27	MATTHES, Eckart, Dr.	Substituierte Pyrimidinnucleoside, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel
US5157114A (en) *	1988-08-19	1992-10-20	Burroughs Wellcome Co.	2',3'-dideoxy-3'-fluoro-5-ethyngluridine
WO1990003978A1 (en) *	1988-10-03	1990-04-19	Stichting Rega Vzw	5-halogeno-3'-fluoro-2',3'-dideoxyuridine compounds and their therapeutic application
WO1992006985A1 (en) *	1990-10-23	1992-04-30	City Of Hope	Mechanism based inhibitors of dna methyltransferase
DD293498A5 (de) *	1989-07-20	1991-09-05	Zi Fuer Molekularbiologie Der Adw,De	Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
AU636678B2 (en) *	1989-11-06	1993-05-06	Nycomed Imaging As	Nucleoside derivatives
GB9003543D0 (en) *	1990-02-16	1990-04-11	Wellcome Found	Therapeutic nucleosides
FR2668153B1 (fr) *	1990-10-22	1995-03-31	Pasteur Merieux Serums Vacc	Nouveaux composes ribonucleosides, leur procede de preparation et les medicaments les contenant.
IT1246983B (it) *	1990-11-13	1994-12-12	Consiglio Nazionale Ricerche	L-2'-desossiuridine e composizioni farmaceutiche che le contengono.
US5180824A (en) *	1990-11-29	1993-01-19	Berlex Biosciences Inc.	6-azido-2-fluoropurine, useful in the synthesis of nucleosides
US5283331A (en) *	1990-12-20	1994-02-01	Nippon Kayaku Kabushiki Kaisha	2-halogeno-oxetanocin A and phosphoric ester thereof
WO1993014103A1 (en) *	1992-01-06	1993-07-22	The Wellcome Foundation Limited	Therapeutic nucleosides
WO1996011204A1 (de) *	1994-10-07	1996-04-18	Max-Delbrück-Centrum für Molekulare Medizin	NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG
US5703058A (en)	1995-01-27	1997-12-30	Emory University	Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en)	1995-01-27	2002-05-21	Emory University	[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5728560A (en) *	1996-06-14	1998-03-17	Enzon, Inc.	Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US6013790A (en) *	1996-09-25	2000-01-11	Board Of Regents University Of Nebraska-Lincoln	Heavily fluorinated sugar analogs
DE19720151A1 (de) *	1997-05-02	1998-11-05	Max Delbrueck Centrum	Chimäre Oligonucleotide und ihre Verwendung
US20020128301A1 (en) *	1998-02-13	2002-09-12	Medivir AB	Non-nucleoside reverse transcriptase inhibitors
US7115584B2 (en) *	1999-01-22	2006-10-03	Emory University	HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en)	1999-01-22	2009-12-22	Emory University	HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
MXPA02008078A (es) *	2000-02-18	2002-11-29	Julio Javier Cristiani	Metodo para el tratamiento o prevencion de infecciones por flavivirus utilizando analogos de nucleosidos.
JP2005503358A (ja) *	2001-06-22	2005-02-03	フアーマセツト・リミテツド	β−２’−または３’−ハロヌクレオシド
US7244717B2 (en) *	2001-08-24	2007-07-17	Koronis Pharmaceuticals, Incorporated	Mutagenic nucleoside analogs for the treatment of viral disease
PL217132B1 (pl)	2010-06-30	2014-06-30	Inst Biochemii I Biofizyki Polskiej Akademii Nauk	Modyfikowane 2',3'-dideoksynukleozydy do leczenia zakażeń szczepami ludzkiego wirusa nabytego niedoboru odporności (HIV) wykazującymi oporność wielolekową, sposób ich wytwarzania oraz farmaceutycznie dopuszczalna forma leku
AU2021237718B2 (en)	2020-03-20	2023-09-21	Gilead Sciences, Inc.	Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE158902C (da) *
GB1189973A (en) *	1969-02-14	1970-04-29	Akad Wissenschaften Ddr	Cytostatically-Active 2',3'-Didesoxy-3'-Fluoropyrimidine-Nucleosides
US3775397A (en) *	1969-11-12	1973-11-27	Akad Wissenschaften Ddr	Novel cytostatic 2',3'-dideoxy-3'-fluoropyrimidine-nucleosides
DD158903A1 (de) *	1981-05-18	1983-02-09	Gotthard Kowollik	Verfahren zur herstellung von 3'-fluor-2',3'-didesoxyadenosin
DD209197A1 (de) *	1981-07-21	1984-04-25	Akad Wissenschaften Ddr	Verfahren zur herstellung von 3'-fluor-2',3'-didesoxyguanosin
JPH02240622A (ja) *	1989-03-14	1990-09-25	Canon Inc	防振光学系

1986
- 1986-07-24 DD DD86292826A patent/DD279407A1/de unknown
1987
- 1987-06-03 DD DD87303489A patent/DD281346A5/de unknown
- 1987-07-21 DE DE8787110542T patent/DE3765045D1/de not_active Expired - Lifetime
- 1987-07-21 DK DK378687A patent/DK378687A/da not_active Application Discontinuation
- 1987-07-21 EP EP87110542A patent/EP0254268B2/de not_active Expired - Lifetime
- 1987-07-21 ES ES87110542T patent/ES2036196T5/es not_active Expired - Lifetime
- 1987-07-23 JP JP62182423A patent/JP2525418B2/ja not_active Expired - Lifetime
1988
- 1988-03-03 AU AU12592/88A patent/AU615431B2/en not_active Expired
- 1988-03-10 NZ NZ223836A patent/NZ223836A/en unknown
- 1988-07-07 CA CA000571404A patent/CA1333390C/en not_active Expired - Lifetime
- 1988-07-15 US US07/223,677 patent/US4963662A/en not_active Expired - Fee Related
1990
- 1990-12-19 GR GR90401088T patent/GR3001214T3/el unknown
1994
- 1994-05-31 CA CA000616868A patent/CA1336820C/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AU615431B2 (en)	1991-10-03
CA1336820C (en)	1995-08-29
EP0254268A2 (de)	1988-01-27
DE3765045D1 (de)	1990-10-25
EP0254268B1 (de)	1990-09-19
GR3001214T3 (en)	1992-07-30
DK378687D0 (da)	1987-07-21
CA1333390C (en)	1994-12-06
DD281346A5 (de)	1990-08-08
ES2036196T5 (es)	1995-08-16
US4963662A (en)	1990-10-16
NZ223836A (en)	1990-12-21
EP0254268A3 (en)	1988-07-13
JP2525418B2 (ja)	1996-08-21
EP0254268B2 (de)	1994-01-12
AU1259288A (en)	1988-11-10
ES2036196T3 (es)	1993-05-16
JPS63107936A (ja)	1988-05-12
DK378687A (da)	1988-01-25

Publication	Publication Date	Title
DD279407A1 (de)	1990-06-06	Verfahren zur herstellung eines mittels gegen aids
DE3689220T2 (de)	1994-02-24	Hemmung der In-vitro-Infektivität und des zytopathischen Effektes von HTLV-III/LAV durch 2'3'-Dideoxyinosin, 2'3'-Dideoxyguanosin oder 2'3'-Dideoxyadenosin.
DE69129331T2 (de)	1998-09-24	Verwendung von inosittriphosphat zur zubereitung von medikamenten
EP0001796B1 (de)	1981-06-10	Mittel gegen Malaria
EP0607775A2 (de)	1994-07-27	Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta
DE69031340T2 (de)	1998-01-15	3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
DE3689221T2 (de)	1994-02-24	Hemmung der In-vitro-Infektivität und des zytopathischen Effektes von HTLV-III/LAV durch 2'3'-Dideoxycytidin.
DE69412662T2 (de)	1999-01-07	Angiotensin II-Antagonisten zur Behandlung von viralen Erkrankungen
EP0374096A1 (de)	1990-06-20	2',3'-Dideoxypurinnucleosid/Purinnucleosid-Phosphorylase-Inhibitor Kombinationstherapie und Zusammensetzungen dafür
AT393506B (de)	1991-11-11	Neue furanuronsaeure-derivate, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
EP0607777A2 (de)	1994-07-27	Verwendung von Leflunomid zur Herstellung von Interleukin 8
DE3619426A1 (de)	1987-12-17	Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion
CH660556A5 (de)	1987-05-15	Therapeutische zubereitung zur behandlung von kardiovaskulaeren krankheiten.
EP0147707B1 (de)	1987-03-18	1,7-Diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur Verwendung bei der Bekämpfung von Krankheiten
DE2728589C3 (de)	1979-06-07	Verwendung von 2-(2,2-disubstituierten)-Äthylimidazolinen bei der Bekämpfung von Diabetes
DE3141970C2 (da)	1987-09-24
DE2833964A1 (de)	1979-03-29	Verfahren zur steigerung der kontraktionsfaehigkeit des herzmuskels
DE2528460A1 (de)	1977-01-13	Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans
EP0669826B1 (de)	1998-08-19	(-)-metrifonat enthaltendes arzneimittel
US5886000A (en)	1999-03-23	Anti-HIV agent
DE1900772B2 (de)	1979-06-07	Salz aus N JS-Dimethylbiguanid und p-Chlorphenoxyessigsäure sowie dieses enthaltende Arzneimittel
DE69630561T2 (de)	2004-06-09	Verwendung von 4-Amino-6-hydroxypyrazolo[3,4-d]pyrimidin zur Herstellung eines blutdrucksenkenden Mittels
DE69421174T2 (de)	2000-02-10	Verwendung von adenosin zur herstellung eines arzneimittels zur behandlung entzüdlicher reaktionen der lunge
DE1792447C3 (de)	1978-05-11	Oral anwendbares, cytostatisches Mittel
US2775539A (en)	1956-12-25	Process of and compositions for combating epileptic seizures with atrolactamide

Legal Events

Date	Code	Title	Description
1993-04-01	NPI	Change in the person, name or address of the patentee (addendum to changes before extension act)
2004-04-28	ASS	Change of applicant or owner	Owner name: THE WELLCOME FOUNDATION LTD., LONDON NW1 2BP Effective date: 19920206
2004-04-28	IF04	In force in the year 2004	Expiry date: 20060725

Date

Code

Title

Description

1993-04-01

NPI

Change in the person, name or address of the patentee (addendum to changes before extension act)

2004-04-28

ASS

Change of applicant or owner

Owner name: THE WELLCOME FOUNDATION LTD., LONDON NW1 2BP

Effective date: 19920206